Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Classical hematology 1Breast 1

Conditions

Head and Neck Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Prostatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 12Docetaxel 7durvalumab 5Gemcitabine 5Trastuzumab 4Radiotherapy 4Surveys and Questionnaires 3Magnetic Resonance Spectroscopy 3tremelimumab 2tisotumab vedotin 2pertuzumab 2motexafin gadolinium 2cemiplimab 2X-Rays 2TH 302 2Ritonavir 2Pemetrexed 2Nivolumab 2Ipilimumab 2Interviews as Topic 2Injections 2Immunoglobulin G 2Cryosurgery 2Cisplatin 2Bortezomib 2Biopsy 2Bariatric Surgery 2zenocutuzumab 1yeast-CEA vaccine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Panobinostat × Head & Neck × Clear all
NCT00670553 2017-05-17

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Novartis

Phase 1 Completed
7 enrolled
GastrointestinalGenitourinaryHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡